Cover Image
市場調查報告書

辛伐他汀(simvastatin)的中國市場分析

Investigation Report on China Simvastatin Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333638
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
辛伐他汀(simvastatin)的中國市場分析 Investigation Report on China Simvastatin Market, 2010-2019
出版日期: 2015年06月25日 內容資訊: 英文 40 Pages
簡介

高血脂症被列為現代社會的三大死亡原因之一,而且發病數年年增加。在中國,由於經濟發展和伙食的變化,人們血液中的脂肪也持續上升。慎重估計結果高血脂症的盛行率達到7∼8%,平均預期也將達10%以上。高齡化社會的來到也是,有1億人以上受降膽固醇治療,對有增進健康、降低膽固醇效果的醫藥品的興趣高漲。作為HMGCoA還原酵素之一的是辛伐他汀(simvastatin),中國在1995年上市,2005年達1億400萬人民幣,2010年1億9700萬人民幣的銷售額。

本報告提供中國的辛伐他汀(simvastatin)的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 辛伐他汀(simvastatin)的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的辛伐他汀(simvastatin)市場概況

  • 中國國內的辛伐他汀(simvastatin)的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 辛伐他汀(simvastatin)銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的辛伐他汀(simvastatin)市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的辛伐他汀(simvastatin)市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 辛伐他汀(simvastatin)的醫院用標準價格

  • Hangzhou MSD Pharmaceutical Co., Ltd (商標名:Shujiangzhi)
  • Sichuan Hairong Pharmaceutical Co., Ltd (商標名:Xindasu)
  • Shandong Lukang Pharmaceutical Co., Ltd (商標名:Xinglu)
  • Guangzhou Nanxin Pharmaceutical Co., Ltd (商標名:Simcor)
  • Cinmed Pharmaceuticals CP (商標名:Jianzhiting)
  • Merck Sharp & Dohme (英國) (商標名:Zocor)

第7章 中國國內的辛伐他汀(simvastatin)的主要製造商

  • Cinmed Pharmaceuticals CP
  • Guangzhou Nanxin Pharmaceutical Co., Ltd
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Sichuan Hairong Pharmaceutical Co., Ltd
  • Merck Sharp & Dohme

第8章 中國的levofloxacin市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506243

Lyperlipidemia, a common disease in present society, has become one of the three health killers with an increasing incidence. Lyperlipidemia can lead to atherosclerosis, coronary heart disease, stroke, myocardial infarction, hemiplegia and so on. Besides, a high level of blood fat will induce such severe diseases as hypertension, hyperglycemia, fatty liver, pancreatitis and fundus hemorrhage which not only cause serious damage but also influence patients' life quality.

With the sustained economic development and the improvements in diet, Chinese people's blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .

Simvastatin, a new generation of HMG-COA reductase inhibitor produced by restructuring lovastatin, was introduced into China by MSD (China) in 1995. Domestic simvastatin was developed by Sichuan Industrial Institute of Antibiotics. Simvastatin develops fast after entering China, sales value being CNY 104 million in 2005 and CNY 197 million in 2010. However, later, its sales began to drop to CNY 156 million in 2014. Hangzhou MSD Pharmaceutical Co., Ltd, Merck Sharp & Dohme (UK), Guangzhou Nanxin Pharmaceutical Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Shandong Lukang Pharmaceutical Co., Ltd occupy the majority of market, among which Hangzhou MSD Pharmaceutical Co., Ltd has the largest market share of 39% for sales value in 2014.

The sales value of simvastatin will stay at a certain level in a given period despite a downtrend in recent years.

Readers can get at least the following information from this report:

  • market size of simvastatin in China
  • price of simvastatin in China
  • market outlook of simvastatin in China

The author suggests the following groups of people purchase this report:

  • manufacturers of lipid-lowering drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Simvastatin

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Simvastatin in China

  • 2.1. Patent and Approval Status of Simvastatin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Simvastatin in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Simvastatin in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Simvastatin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Simvastatin in Chinese Hospitals in 2014

  • 6.1. Hangzhou MSD Pharmaceutical Co., Ltd (Trade Name: Shujiangzhi)
  • 6.2. Sichuan Hairong Pharmaceutical Co., Ltd (Trade Name: Xindasu)
  • 6.3. Shandong Lukang Pharmaceutical Co., Ltd (Trade Name: Xinglu)
  • 6.4. Guangzhou Nanxin Pharmaceutical Co., Ltd (Trade Name: Simcor)
  • 6.5. Cinmed Pharmaceuticals CP (Trade Name: Jianzhiting)
  • 6.6. Merck Sharp & Dohme (UK) (Trade Name: Zocor)

7. Major Manufacturers of Simvastatin in Chinese Market, 2010-2014

  • 7.1. Cinmed Pharmaceuticals CP
  • 7.2. Guangzhou Nanxin Pharmaceutical Co., Ltd
  • 7.3. Shandong Lukang Pharmaceutical Co., Ltd
  • 7.4. Sichuan Hairong Pharmaceutical Co., Ltd
  • 7.5. Merck Sharp & Dohme

8. Market Outlook of Simvastatin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Simvastatin in China
  • Chart Approval Information of Simvastatin in China
  • Chart Sales Status of Simvastatin in China
  • Chart Sales Value of Simvastatin in China, 2010-2014
  • Chart Sales Value of Simvastatin in Some Regions in China, 2010-2014
  • Chart Sales Volume of Simvastatin in China, 2010-2014
  • Chart Sales Volume of Simvastatin in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Simvastatin for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Made by Hangzhou MSD in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Made by Merck Sharp & Dohme (UK) in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Made by Guangzhou Nanxin in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Made by Cinmed in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Made by Shandong Lukang Pharmaceutical in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Pills in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Simvastatin Capsules in China, 2010-2014
  • Chart Price of Simvastatin Made by Hangzhou MSD Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Simvastatin Made by Sichuan Hairong Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Simvastatin Made by Shandong Lukang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Simvastatin Made by Guangzhou Nanxin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Simvastatin Made by Cinmed Pharmaceuticals CP in Some Chinese Cities in 2014
  • Chart Price of Simvastatin Made by Merck Sharp & Dohme (UK) in Some Chinese Cities in 2014
Back to Top